The overarching goal of our research is to devise novel antitumour immunotherapeutic modalities that can cure cancer. We have developed a series of human cell-based artificial antigen-presenting cells (APC) that can generate in vitro large numbers of HLA class I-restricted CD8 T cells, class II-restricted CD4 T cells, polyclonal CD3 T cells and CD1d-restricted iNKT cells. Using these artificial APC, we are conducting basic, translational, and clinical research in human T cell immunology. We are particularly interested in understanding how the interactions between T cells and APC affect priming, expansion, persistence and differentiation of T cells. We also seek to clarify how this leads to the subsequent generation and maintenance of T cell memory. Aspiring researchers and trainees who are eager to conquer cancer by harnessing the power of immunity are welcome to our laboratory.
A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects.
Nat Med. 2018 Feb 05;:
MHC class I loaded ligands from breast cancer cell lines: A potential HLA-I-typed antigen collection.
J Proteomics. 2018 Mar 30;176:13-23
J Immunol. 2018 Jan 15;200(2):500-511
Sci Immunol. 2017 Apr 21;2(10):
HLA-DP(84Gly) constitutively presents endogenous peptides generated by the class I antigen processing pathway.
Nat Commun. 2017 May 10;8:15244
Correction: Key Residues at Third CDR3β Position Impact Structure and Antigen Recognition of Human Invariant NK TCRs.
J Immunol. 2017 May 01;198(9):3757
JCI Insight. 2017 Jan 26;2(2):e89580
Identification of Functional and Expression Polymorphisms Associated With Risk for Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis.
Arthritis Rheumatol. 2017 May;69(5):1054-1066
Key Residues at Third CDR3β Position Impact Structure and Antigen Recognition of Human Invariant NK TCRs.
J Immunol. 2017 Feb 01;198(3):1056-1065
Generating De Novo Antigen-specific Human T Cell Receptors by Retroviral Transduction of Centric Hemichain.
J Vis Exp. 2016 Oct 25;(116):
Senior Scientist, Princess Margaret Cancer Centre
Senior Scientist, Associate Director for Research, Immune Therapy Program, Princess Margaret Cancer Centre
Clinician Scientist, Ontario Institute for Cancer Research
Associate Professor, Department of Immunology, University of Toronto